Delivery Order SPE2DB24D1205-SPE2DB25FCZDC
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron ODT 4 MG tablets (30-count) with a contract ceiling value of $1,512.72. This firm fixed price delivery order, which is set to be completed by August 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The award was competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron HCl 4 mg tablets (30-count packaging) with a ceiling value of $25,134.02. This firm fixed-price delivery order, which is not set-aside, represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be performed and delivered from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron HCl 4 mg tablets (30-count packaging) on July 21, 2025, with a ceiling value of $2,110.45 and an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a single delivery order under...
- The Defense Logistics Agency awarded a delivery order valued at $3,326.60 to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron HCL 4 mg tablets (500 count). The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award status. Performance is scheduled to conclude by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ondansetron HCl 4 mg tablets in quantities of 30, with a ceiling value of $8,454.17. This is a firm fixed-price delivery order with an ultimate completion date of August 1, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This...
- The Defense Logistics Agency awarded a delivery order valued at $14,466.96 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ondansetron HCL 4 mg tablets in quantities of 30. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30, with a ceiling value of $13,127.44. This contract employs firm fixed price terms and carries an ultimate completion date of July 31, 2025. The award utilized no set-aside designation, indicating competitive procurement through open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—which also serves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count packages) with a ceiling value of $13,483.05. This firm fixed-price delivery order, with an ultimate completion date of July 25, 2025, represents a non-set-aside, competitively awarded contract. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed...
- The Defense Logistics Agency awarded a $5,629.86 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is located in Conshohocken, Pennsylvania, which is also the headquarters location of the prime contractor. This delivery order is issued...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZDCDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ondansetron HCL 4 mg tablets (30-count) with a ceiling value of $15,097.14. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The award was made on a firm fixed-price basis with no set-aside designation, indicating competitive award to the vendor. Performance will be fulfilled from the contractor's location in Conshohocken, Pennsylvania, with a completion date of August 1, 2025. This delivery order reflects the ongoing pharmaceutical supply relationship between AmerisourceBergen Drug Corp and the Defense Logistics Agency's Medical Supply Chain, through which the contractor supplies a comprehensive range of medications and medical supplies to support military and federal healthcare systems. Ondansetron HCL, an antiemetic medication commonly used in medical settings, represents one component of the broader pharmaceutical commodities delivered under the company's DLA prime vendor agreement. AmerisourceBergen's federal contract portfolio demonstrates consistent capability to fulfill federal medical procurement requirements through competitive delivery orders across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.1k | 7/31/25 |